SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
申请人:BlinkBio, Inc.
公开号:US20170202970A1
公开(公告)日:2017-07-20
Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF
申请人:EPIZYME, INC.
公开号:US20150344434A1
公开(公告)日:2015-12-03
Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described.
Alternative synthetic routes to the title ring systems were examined: the isothiazolopyridines 5a,b and 10 were obtained by single step procedures from pyridine derivatives.
CHIMICHI, STEFANO;NESI, RODOLFO;PONTICELLI, FABIO;TEDESCHI, PIERO, J. CHEM. SOC. PERKIN TRANS. PT 1,(1990) N, C. 1477-1480